South Korea
· Delayed Price · Currency is KRW NGeneBio Statistics
Total Valuation
NGeneBio has a market cap or net worth of KRW 29.26 billion. The enterprise value is 37.61 billion.
| Market Cap | 29.26B |
| Enterprise Value | 37.61B |
Important Dates
The next estimated earnings date is Friday, March 21, 2025.
| Earnings Date | Mar 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
NGeneBio has 13.74 million shares outstanding. The number of shares has increased by 2.40% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 13.74M |
| Shares Change (YoY) | +2.40% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 19.70% |
| Owned by Institutions (%) | 0.99% |
| Float | 9.55M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.45 |
| PB Ratio | 3.16 |
| P/TBV Ratio | 19.09 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.45 |
| EV / Sales | 6.09 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.55 |
Financial Position
The company has a current ratio of 0.57, with a Debt / Equity ratio of 1.36.
| Current Ratio | 0.57 |
| Quick Ratio | 0.44 |
| Debt / Equity | 1.36 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.89 |
| Interest Coverage | -8.58 |
Financial Efficiency
Return on equity (ROE) is -89.89% and return on invested capital (ROIC) is -36.48%.
| Return on Equity (ROE) | -89.89% |
| Return on Assets (ROA) | -22.61% |
| Return on Capital (ROIC) | -36.48% |
| Revenue Per Employee | 88.23M |
| Profits Per Employee | -218.91M |
| Employee Count | 70 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 1.77 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -58.18% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -58.18% |
| 50-Day Moving Average | 2,620.80 |
| 200-Day Moving Average | 3,462.43 |
| Relative Strength Index (RSI) | 38.50 |
| Average Volume (20 Days) | 340,956 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NGeneBio had revenue of KRW 6.18 billion and -15.32 billion in losses. Loss per share was -1,188.82.
| Revenue | 6.18B |
| Gross Profit | 2.75B |
| Operating Income | -14.57B |
| Pretax Income | -11.85B |
| Net Income | -15.32B |
| EBITDA | -12.26B |
| EBIT | -14.57B |
| Loss Per Share | -1,188.82 |
Balance Sheet
The company has 5.70 billion in cash and 13.10 billion in debt, giving a net cash position of -7.40 billion or -538.75 per share.
| Cash & Cash Equivalents | 5.70B |
| Total Debt | 13.10B |
| Net Cash | -7.40B |
| Net Cash Per Share | -538.75 |
| Equity (Book Value) | 9.64B |
| Book Value Per Share | 674.49 |
| Working Capital | -8.99B |
Cash Flow
In the last 12 months, operating cash flow was -14.04 billion and capital expenditures -723.38 million, giving a free cash flow of -14.76 billion.
| Operating Cash Flow | -14.04B |
| Capital Expenditures | -723.38M |
| Free Cash Flow | -14.76B |
| FCF Per Share | -1,074.60 |
Margins
Gross margin is 44.46%, with operating and profit margins of -235.89% and -170.46%.
| Gross Margin | 44.46% |
| Operating Margin | -235.89% |
| Pretax Margin | -191.84% |
| Profit Margin | -170.46% |
| EBITDA Margin | -198.55% |
| EBIT Margin | -235.89% |
| FCF Margin | n/a |
Dividends & Yields
NGeneBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.40% |
| Shareholder Yield | -2.40% |
| Earnings Yield | -55.81% |
| FCF Yield | -50.45% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NGeneBio has an Altman Z-Score of -2.8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.8 |
| Piotroski F-Score | n/a |